Browsing by Author Strickland, A. H.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)Citation
2013Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trialGebski, Val; Parry, M M; Pavlakis, Nick; Zannino, Diana; Dobrovic, Alexander N; Ganju, V.; Mellor, D; Strickland, A. H.; Tebbutt, Niall C; van Hazel, Guy; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreDocetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial, British Journal of Cancer, vol.108, 4, 2013,pp 771-774
2006Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.Marx, Gavin; Yip, Desmond; Cheong, K.; Chrystal, K.; Galani, E.; Gallagher, C.; Harper, P. G.; Lofts, F.; Steer, Christopher B.; Strickland, A. H.; Thomas, H.; Centre Regional Ed - Orange; MedicineGemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study., Gynecologic oncology, vol.103,(2),2006,pp 439-445
2016Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trialFerraro, Danielle Angela; Gebski, Val; Hall, Merryn; Pavlakis, Nick; Sjoquist, Katrin; Veillard, Anne-Sophie; Wong, Nicole; Cooray, Prasad; Ganju, V.; Price, Timothy; Shannon, Jenny; Strickland, A. H.; Tebbutt, Niall; Underhill, Craig; Varma, S; Young, Rosemary; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentrePanitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial, British Journal of Cancer, vol.114, 5, 2016,pp 505-509
2014Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trialEl-Tahche, Fabyolla; Shannon, Jenny; Alcindor, Thierry; Au, Heather-Jane; Easaw, Jay C; et al, Various; Jeffery, Mark; Jonker, Derek J.; Kotb, Rami; Moore, Malcolm; Ng, Siobhan; Ringash, Jolie; Sabesan, Sabe; Salim, Muhammad; Shapiro, Jeremy; Siu, Lillian L; Strickland, A. H.; Zalcberg, John; Central Clinical School: Medicine; Nepean Clinical School: MedicineQuality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial, Cancer, vol.120, 2, 2014,pp 181-189
2010Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trialCummins, Michelle; Gebski, Val; Sourjina, Tatiana; Stockler, Martin; Ganju, Vinod; Gibbs, David; Strickland, A. H.; Tebbutt, Niall C; van Hazel, Guy; Zalcberg, John; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRandomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial, British Journal of Cancer, vol.102, 3,pp 475-481
2016Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II TrialMartin, Andrew; Pavlakis, Nick; Simes, Robert John; Sjoquist, Katrin; Tsobanis, Eric; Wong, Ka (Mark); Yip, Sonia; Alcindor, Thierry; bang, Yungjue; Burnell, Margot J; Cho, Jaeyong; Goldstein, David; Kang, Yoon-Koo; Kim, Jinwon; Lee, Jeeyun; Lipton, Lara; O'Callaghan, Chris; Rha, Sunyoung; Strickland, A. H.; Tebbutt, Niall; Zalcberg, John; NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); NH&MRC Clinical Trials CentreRegorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II Trial, Journal of Clinical Oncology, vol.34, 23, 2016,pp 2728-2735
2011Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumabCummins, Michelle; Marx, Gavin; Shannon, Jenny; Simes, Robert John; Wilson, Kate; Zannino, Diana; Abdi, Ehtesham A; Blum, R; Chantrill, L; Goldstein, D; Karapetis, Christos; Lowenthal, Raymond M.; Murphy, F; Nayagam, S; Price, Timothy; Strickland, A. H.; Tebbutt, Niall C; School of Public Health: NH&MRC Clinical Trials Centre; Medicine; Nepean Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRisk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab, Annals of Oncology, vol.22, 8, 2011,pp 1834-1838
2016SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal CancerGebski, Val; et al, Various; Ferguson, Tom; Findlay, Michael; Hazel, Guy; Heinemann, Volker; Peeters, Marc; Perez, D; Ricke, Jens; Robinson, Bridget; Sharma, Navesh; Strickland, A. H.; NH&MRC Clinical Trials CentreSIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.34, 15, 2016,pp 1723-1731